HUE038543T2 - MGBG-t tartalmazó szabályozott kibocsátású orális gyógyszerészeti dózis-formák - Google Patents
MGBG-t tartalmazó szabályozott kibocsátású orális gyógyszerészeti dózis-formákInfo
- Publication number
- HUE038543T2 HUE038543T2 HUE12736469A HUE12736469A HUE038543T2 HU E038543 T2 HUE038543 T2 HU E038543T2 HU E12736469 A HUE12736469 A HU E12736469A HU E12736469 A HUE12736469 A HU E12736469A HU E038543 T2 HUE038543 T2 HU E038543T2
- Authority
- HU
- Hungary
- Prior art keywords
- mgbg
- dosage forms
- controlled release
- pharmaceutical dosage
- oral pharmaceutical
- Prior art date
Links
- 238000013270 controlled release Methods 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/13—Amines containing three or more amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/10—Hydrazines
- C07C243/12—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms
- C07C243/16—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
- C07C251/04—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C251/10—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
- C07C251/12—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton being acyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/72—Hydrazones
- C07C251/74—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C251/78—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161434269P | 2011-01-19 | 2011-01-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE038543T2 true HUE038543T2 (hu) | 2018-10-29 |
Family
ID=46516367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE12736469A HUE038543T2 (hu) | 2011-01-19 | 2012-01-19 | MGBG-t tartalmazó szabályozott kibocsátású orális gyógyszerészeti dózis-formák |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US8858991B2 (enExample) |
| EP (1) | EP2665471B1 (enExample) |
| CA (1) | CA2825014C (enExample) |
| DK (1) | DK2665471T3 (enExample) |
| ES (1) | ES2662373T3 (enExample) |
| HU (1) | HUE038543T2 (enExample) |
| NO (1) | NO2665471T3 (enExample) |
| PL (1) | PL2665471T3 (enExample) |
| PT (1) | PT2665471T (enExample) |
| WO (1) | WO2012100043A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2121586B1 (en) | 2007-03-09 | 2017-03-08 | Pathologica LLC | Mgbg for the regulation of osteopontin and the treatment of multiple sclerosis |
| WO2011009039A2 (en) | 2009-07-16 | 2011-01-20 | Pathologica Llc | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease |
| US9675566B2 (en) | 2009-07-16 | 2017-06-13 | Pathologica Llc | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing |
| NO2665471T3 (enExample) | 2011-01-19 | 2018-05-26 | ||
| BR112015016189A8 (pt) | 2013-01-08 | 2019-10-22 | Pathologica Llc | usos de metilglioxal bis (guanilhidrazona) (mgbg), uso de metilglioxal bis (guanilhidrazona) (mgbg) e um agente e composição farmacêutica |
| US10987368B2 (en) * | 2014-12-08 | 2021-04-27 | Glycom A/S | Synthetic composition for preventing or treating CVD |
| US10881674B2 (en) | 2014-12-08 | 2021-01-05 | Glycom A/S | Synthetic composition for treating metabolic disorders |
| JP7402225B2 (ja) | 2018-05-11 | 2023-12-20 | ロード アイランド ホスピタル | ヌクレオシド系逆転写酵素阻害剤を用いて関節障害を処置するための組成物および方法 |
| EP3914604A4 (en) | 2019-01-25 | 2022-10-19 | Brown University | COMPOSITIONS AND METHODS FOR TREATMENT, PREVENTION OR REVERSE OF AGE-RELATED INFLAMMATION AND DISEASE |
| WO2025075624A1 (en) * | 2023-10-05 | 2025-04-10 | Mirum Pharmaceuticals, Inc. | Pharmaceutical compositions comprising maralixibat and uses thereof |
| US12296050B2 (en) | 2023-10-05 | 2025-05-13 | Mirum Pharmaceuticals, Inc. | Pharmaceutical compositions comprising maralixibat and uses thereof |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4201788A (en) | 1976-10-20 | 1980-05-06 | University Patents, Inc. | Process for alleviating proliferative skin diseases |
| US5614557A (en) | 1977-07-11 | 1997-03-25 | Marion Merrell Et Compagnie C/O Merrell Pharmaceuticals Inc. | Method of controlling tumor growth rate |
| US4520031A (en) * | 1981-06-01 | 1985-05-28 | The United States Of America As Represented By The Secretary Of Department Of Health And Human Services | Method for reducing toxic effects of methyl-glyoxal bis-guanylhydrazone |
| CA1338366C (en) | 1984-12-26 | 1996-06-04 | Algis Anilionis | Efficient prokaryotic expression system |
| US5580715A (en) | 1994-08-05 | 1996-12-03 | The Regents Of The University Of California | Diagnosis of cancer having clonal macrophage involvement |
| US5639600A (en) | 1994-08-05 | 1997-06-17 | The Regents Of The University Of California | Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement |
| US5698563A (en) | 1995-01-13 | 1997-12-16 | Alteon Inc. | Bis- hydrazones! |
| US8198334B2 (en) | 1997-10-27 | 2012-06-12 | Pathologica Llc | Methods for modulating macrophage proliferation in ocular disease using polyamine analogs |
| US7087648B1 (en) | 1997-10-27 | 2006-08-08 | The Regents Of The University Of California | Methods for modulating macrophage proliferation using polyamine analogs |
| US6169115B1 (en) | 1998-05-22 | 2001-01-02 | Rima Kaddurah-Daouk | Use of aminoguanidine analogs for the treatment of diseases of the nervous system |
| US6544541B1 (en) | 1999-06-02 | 2003-04-08 | Cardiovascular Solutions, Inc. | Devices and compounds for treating arterial restenosis |
| CA2400374A1 (en) | 2000-02-18 | 2001-08-23 | Adrian Gilbert | Oral, nasal and pulmonary dosage formualtions of copolymer 1 |
| US7754765B2 (en) | 2000-12-01 | 2010-07-13 | Radical Vision Therapeutics Inc | Copper chelators for treating ocular inflammation |
| US6991809B2 (en) * | 2001-06-23 | 2006-01-31 | Lyotropic Therapeutics, Inc. | Particles with improved solubilization capacity |
| CA2456034A1 (en) * | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Sustained-release medicines |
| WO2003016491A2 (en) | 2001-08-15 | 2003-02-27 | The Regents Of The University Of California | Retrovirus isolated from mantle histiocytes in mantle cell lymphoma |
| US7211602B2 (en) | 2001-11-16 | 2007-05-01 | Als Therapy Development Foundation, Inc. | Treatment of neurodegenerative disorders through the modulation of the polyamine pathway |
| US7622117B2 (en) | 2002-04-17 | 2009-11-24 | Dynamis Therapeutics, Inc. | 3-deoxyglucosone and skin |
| EP1389480A1 (en) | 2002-08-14 | 2004-02-18 | Mondobiotech Interferon SA | Therapeutical use of guanylhydrazones for the inhibition of CD83 dependent processes and dendritic cell maturation |
| EP1613263A4 (en) | 2003-01-31 | 2007-11-28 | Pathologica Llc | MONITORING AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS |
| CA2519211A1 (en) * | 2003-03-17 | 2004-09-30 | Takeda Pharmaceutical Company Limited | Release control compositions |
| GB2400318B (en) | 2003-04-08 | 2005-08-10 | Novartis Ag | Pharmaceutical composition comprising an S1P receptor agonist |
| US20050042277A1 (en) * | 2003-07-17 | 2005-02-24 | Irukulla Srinivas | Pharmaceutical compositions having a swellable coating |
| US20050025825A1 (en) * | 2003-07-31 | 2005-02-03 | Xanodyne Pharmacal, Inc. | Tranexamic acid formulations with reduced adverse effects |
| US20050113455A1 (en) | 2003-10-22 | 2005-05-26 | Bergeron Raymond J.Jr. | Method and composition for amelioration of pain |
| US7445794B1 (en) * | 2004-04-29 | 2008-11-04 | The Regents Of The University Of Colorado | Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors |
| US20060189546A1 (en) | 2005-01-28 | 2006-08-24 | Ajami Alfred M | Compounds for treating autoimmune and demyelinating diseases |
| PL1916995T5 (pl) * | 2005-07-29 | 2022-10-31 | Stichting Groningen Centre For Drug Research | Kontrolowany wartością ph impulsowy układ podawczy, sposoby przygotowania i zastosowanie |
| US8912214B2 (en) | 2005-07-29 | 2014-12-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of Chk2 kinase inhibitors for cancer treatment |
| EP1937235B1 (en) * | 2005-09-23 | 2015-07-01 | Pathologica, LLC. | Methods for treating viral infections using polyamine analogs |
| WO2007047408A2 (en) * | 2005-10-12 | 2007-04-26 | Pathologica, Llc. | Promac signature application |
| US20110091418A1 (en) | 2006-09-25 | 2011-04-21 | Pathlogica, LLC | Methods for treating viral infections using polyamine analogs |
| EP2164698A1 (en) | 2007-03-09 | 2010-03-24 | Sustainable Solutions, Inc. | Regenerated cotton board material and method of manufacture |
| EP2121586B1 (en) | 2007-03-09 | 2017-03-08 | Pathologica LLC | Mgbg for the regulation of osteopontin and the treatment of multiple sclerosis |
| WO2008148798A2 (en) * | 2007-06-04 | 2008-12-11 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| WO2009018368A1 (en) | 2007-07-30 | 2009-02-05 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders |
| WO2010037395A2 (en) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| WO2010045265A1 (en) | 2008-10-13 | 2010-04-22 | Biovista, Inc. | Compositions and methods for treating multiple sclerosis |
| CN102281870B (zh) * | 2008-12-10 | 2015-03-04 | 安徽中人科技有限责任公司 | 新型控释组合物 |
| US20100189788A1 (en) | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline base formulation |
| US9675566B2 (en) | 2009-07-16 | 2017-06-13 | Pathologica Llc | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing |
| WO2011009039A2 (en) * | 2009-07-16 | 2011-01-20 | Pathologica Llc | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease |
| EP2283830A1 (en) * | 2009-07-23 | 2011-02-16 | Actogenix N.V. | Aqueous enteric capsule coating |
| EP2343075A1 (en) | 2010-01-04 | 2011-07-13 | Neurotec Pharma, S.L. | Diazoxide for use in the treatment a central nervous system (CNS) autoimmune demyelinating disease |
| TWI590821B (zh) * | 2011-01-18 | 2017-07-11 | 輝瑞有限公司 | 固體分子分散液 |
| NO2665471T3 (enExample) | 2011-01-19 | 2018-05-26 | ||
| BR112015016189A8 (pt) | 2013-01-08 | 2019-10-22 | Pathologica Llc | usos de metilglioxal bis (guanilhidrazona) (mgbg), uso de metilglioxal bis (guanilhidrazona) (mgbg) e um agente e composição farmacêutica |
-
2012
- 2012-01-19 NO NO12736469A patent/NO2665471T3/no unknown
- 2012-01-19 DK DK12736469.3T patent/DK2665471T3/en active
- 2012-01-19 US US13/354,076 patent/US8858991B2/en active Active
- 2012-01-19 ES ES12736469.3T patent/ES2662373T3/es active Active
- 2012-01-19 EP EP12736469.3A patent/EP2665471B1/en active Active
- 2012-01-19 WO PCT/US2012/021853 patent/WO2012100043A2/en not_active Ceased
- 2012-01-19 PL PL12736469T patent/PL2665471T3/pl unknown
- 2012-01-19 HU HUE12736469A patent/HUE038543T2/hu unknown
- 2012-01-19 PT PT127364693T patent/PT2665471T/pt unknown
- 2012-01-19 CA CA2825014A patent/CA2825014C/en active Active
-
2014
- 2014-09-09 US US14/480,847 patent/US9668988B2/en not_active Expired - Fee Related
-
2017
- 2017-05-01 US US15/583,697 patent/US10881626B2/en not_active Expired - Fee Related
-
2020
- 2020-12-04 US US17/111,895 patent/US20210085625A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2665471B1 (en) | 2017-12-27 |
| US8858991B2 (en) | 2014-10-14 |
| DK2665471T3 (en) | 2018-03-19 |
| US10881626B2 (en) | 2021-01-05 |
| PT2665471T (pt) | 2018-03-21 |
| CA2825014C (en) | 2019-01-08 |
| ES2662373T3 (es) | 2018-04-06 |
| US20210085625A1 (en) | 2021-03-25 |
| WO2012100043A2 (en) | 2012-07-26 |
| US9668988B2 (en) | 2017-06-06 |
| CA2825014A1 (en) | 2012-07-26 |
| WO2012100043A3 (en) | 2012-10-18 |
| US20180050000A1 (en) | 2018-02-22 |
| NO2665471T3 (enExample) | 2018-05-26 |
| EP2665471A2 (en) | 2013-11-27 |
| PL2665471T3 (pl) | 2018-06-29 |
| EP2665471A4 (en) | 2014-07-23 |
| US20120269891A1 (en) | 2012-10-25 |
| US20140377345A1 (en) | 2014-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201307862B (en) | Controlled release pharmaceutical dosage forms | |
| IL227383A0 (en) | Extended-release oral dosage forms containing tsucitinib | |
| IL228709A0 (en) | Dosage unit form for oral administration | |
| PT3653223T (pt) | Dispositivo para a entrega oral de compostos terapêuticos | |
| PL2665471T3 (pl) | Doustne farmaceutyczne postacie dawkowane o kontrolowanym uwalnianiu zawierające mgbg | |
| SG10201604667YA (en) | Pharmaceutical preparation | |
| ZA201402669B (en) | Solution for oral administration | |
| IL232305B (en) | Pharmacy preparations | |
| SG11201403875VA (en) | Oral pharmaceutical composition | |
| PT2726064T (pt) | Forma de dosagem oral de libertação controlada compreendendo oxicodona | |
| GB201105298D0 (en) | Pharmaceutical preparation | |
| IL234931A0 (en) | Stable immediate-release oral pharmaceutical preparations containing prasugrel | |
| PL2691119T3 (pl) | Preparat farmaceutyczny | |
| ZA201201424B (en) | Pharmaceutical dosage form | |
| GB201111577D0 (en) | Pharmaceutical formulations | |
| GB201018760D0 (en) | An oral dosage form |